Fund

Tianjin Venture Capital

天创资本

elsewhere's corpus has no profile material on Tianjin Venture Capital (天创资本) itself — no founding story, fund size, or strategy description — so a full profile can't be written from what's on file. What the record does show is its deal activity: it co-led SmartX's Series C round alongside Huaye Tiancheng Capital in 2020 ; it joined the Series B of gene-editing company YolTech Therapeutics (尧唐生物) in 2025 and doubled down in the nearly RMB 500 million Series C led by Loyal Valley Capital in May 2026 ; and it was among the institutional investors in LimX Dynamics' $200 million Series B in early 2026 . Read together, the visible footprint is a fund active across enterprise cloud, biotech, and robotics — but anything beyond these portfolio sightings is outside elsewhere's current coverage.

AI-generated — may contain errors, please verify.

Tianjin Venture CapitalFund
天创资本
渲染中…
Mentioned in 5 articles

Coverage